Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PAIN INSTITUTE OF NASHVILLE, PLC

NPI: 1073049102 · CLARKSVILLE, TN 37043 · Pain Clinic/Center · NPI assigned 05/10/2017

$55K
Total Medicaid Paid
61,566
Total Claims
37,181
Beneficiaries
25
Codes Billed
2018-11
First Month
2024-05
Last Month

Provider Details

Authorized OfficialWOOD, RON (BILLING MANAGER)
NPI Enumeration Date05/10/2017

Related Entities

Other providers sharing the same authorized official: WOOD, RON

ProviderCityStateTotal Paid
BECK, GRIFFITH, CIRILLO, AND PATEL, P.A. PRINCE FREDERICK MD $15K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,365 $11.76
2019 11,203 $6K
2020 10,915 $12K
2021 19,521 $12K
2022 9,471 $11K
2023 7,294 $10K
2024 1,797 $3K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 15,825 9,611 $31K
G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes 7,510 4,533 $7K
96136 6,068 3,634 $6K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 14,369 8,507 $2K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 9,875 5,891 $2K
96138 816 519 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 85 78 $2K
96132 273 177 $1K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 4,646 2,726 $859.69
96127 669 430 $324.73
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 27 18 $213.98
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 141 63 $148.34
96146 638 493 $47.73
93922 28 12 $33.00
95923 14 12 $25.75
87500 27 18 $16.46
87640 27 18 $16.46
87641 27 18 $16.46
96120 195 170 $4.02
96103 195 170 $2.38
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 18 12 $0.00
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 27 18 $0.00
81002 21 17 $0.00
80305 31 24 $0.00
95921 14 12 $0.00